300 related articles for article (PubMed ID: 7832633)
21. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
Polzer S; Dittmar MT; Schmitz H; Schreiber M
Virology; 2002 Dec; 304(1):70-80. PubMed ID: 12490404
[TBL] [Abstract][Full Text] [Related]
22. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
23. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
[TBL] [Abstract][Full Text] [Related]
24. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.
Harrop HA; Coombe DR; Rider CC
AIDS; 1994 Feb; 8(2):183-92. PubMed ID: 8043225
[TBL] [Abstract][Full Text] [Related]
25. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
26. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
[TBL] [Abstract][Full Text] [Related]
27. Combination effect on HIV infection in vitro of soluble CD4 and HIV-neutralizing antibodies.
Hansen JE; Sørensen AM; Olofsson S; Osinaga E; Roseto A
Arch Virol; 1994; 134(1-2):179-84. PubMed ID: 8279954
[TBL] [Abstract][Full Text] [Related]
28. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
Gray ES; Moore PL; Pantophlet RA; Morris L
J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
[TBL] [Abstract][Full Text] [Related]
29. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
30. Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.
Sourial S; Nilsson C; Wärnmark A; Achour A; Harris RA
Curr HIV Res; 2006 Apr; 4(2):229-37. PubMed ID: 16611061
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop.
Hansen JE; Jansson B; Gram GJ; Clausen H; Nielsen JO; Olofsson S
Arch Virol; 1996; 141(2):291-300. PubMed ID: 8634021
[TBL] [Abstract][Full Text] [Related]
32. Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope.
Takizawa M; Miyauchi K; Urano E; Kusagawa S; Kitamura K; Naganawa S; Murakami T; Honda M; Yamamoto N; Komano J
AIDS; 2011 Nov; 25(18):2209-16. PubMed ID: 21866041
[TBL] [Abstract][Full Text] [Related]
33. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
Grimaila RJ; Fuller BA; Rennert PD; Nelson MB; Hammarskjöld ML; Potts B; Murray M; Putney SD; Gray G
J Virol; 1992 Apr; 66(4):1875-83. PubMed ID: 1548744
[TBL] [Abstract][Full Text] [Related]
35. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
[TBL] [Abstract][Full Text] [Related]
36. Neutralization epitopes of the HIV-1 primary isolate DH012.
Zhu C; Matthews TJ; Chen CH
Vaccine; 2003 Jul; 21(23):3301-6. PubMed ID: 12804861
[TBL] [Abstract][Full Text] [Related]
37. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
Cao J; Sullivan N; Desjardin E; Parolin C; Robinson J; Wyatt R; Sodroski J
J Virol; 1997 Dec; 71(12):9808-12. PubMed ID: 9371651
[TBL] [Abstract][Full Text] [Related]
38. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
39. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
Sullivan N; Sun Y; Binley J; Lee J; Barbas CF; Parren PW; Burton DR; Sodroski J
J Virol; 1998 Aug; 72(8):6332-8. PubMed ID: 9658072
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
